Peter Clark

5.2k total citations · 2 hit papers
48 papers, 3.8k citations indexed

About

Peter Clark is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Peter Clark has authored 48 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 19 papers in Molecular Biology and 15 papers in Epidemiology. Recurrent topics in Peter Clark's work include Cancer therapeutics and mechanisms (13 papers), Lung Cancer Research Studies (13 papers) and Neuroendocrine Tumor Research Advances (12 papers). Peter Clark is often cited by papers focused on Cancer therapeutics and mechanisms (13 papers), Lung Cancer Research Studies (13 papers) and Neuroendocrine Tumor Research Advances (12 papers). Peter Clark collaborates with scholars based in United Kingdom, United States and Australia. Peter Clark's co-authors include M L Slevin, Sally Stenning, Ruth E. Langley, J Bancewicz, William Allum, Joachim von Pawel, Marc B. Brown, P. F. M. Wrigley, David J. Potter and R H Reznek and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Peter Clark

48 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer

2009 721 citations Sally Stenning, Peter Clark et al. Journal of Clinical Oncology profile →
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 694 citations Peter Clark, Graham Ross et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Peter Clark

Since Specialization

Citations

This map shows the geographic impact of Peter Clark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Clark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Clark more than expected).

Fields of papers citing papers by Peter Clark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Clark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Clark. The network helps show where Peter Clark may publish in the future.

Co-authorship network of co-authors of Peter Clark

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Clark. A scholar is included among the top collaborators of Peter Clark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Clark. Peter Clark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Metastatic breast cancer presenting as sequential cranial nerve palsy: a case report 2014 ·Journal of Medical Case Reports ·(unknown), (unknown), Peter Clark	6
2	NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosis 2013 ·The Lancet Respiratory Medicine ·(unknown), Helen Knight, Peter Clark	2
3	The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study 2010 ·PLoS ONE ·Joseph J. Sacco, (unknown), Fergus Macbeth, A Bagust, Peter Clark	166
4	Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia–dysplasia–adenocarcinoma sequence 2010 ·Journal of Clinical Pathology ·Stephen J. Hayes, Sajad Ahmed, Peter Clark	20
5	Multiple adenomatoid tumours in the liver and peritoneum 2007 ·Journal of Clinical Pathology ·Stephen J. Hayes, Peter Clark, Richard T. Mathias, Laura Formela, (unknown), Gordon Armstrong	20
6	Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study 2003 ·British Journal of Cancer ·Helen Innes, David B. Smith, S.M. O'Reilly, Peter Clark, V. Kelly, E. Marshall	93
7	A Phase I Trial of a 5-Day Schedule of Intravenous Topotecan and Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer 2001 ·Oncology ·P A O'Neill, Peter Clark, (unknown), Ernest Marshall, (unknown), Graham Ross	12
8	Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients 2000 ·Supportive Care in Cancer ·Ernest Marshall, David B. Smith, S.M. O'Reilly, (unknown), V. Kelly, Peter Clark	10
9	Current Role of Oral Etoposide in the Management of Small Cell Lung Cancer 1999 ·Drugs ·Peter Clark	4
10	Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours 1999 ·British Journal of Cancer ·Sophie D. Fosså, Sally Stenning, A. Gerl, (unknown), Peter Clark, P M Wilkinson, William G. Jones, M.V. Williams, R.T.D. Oliver, ES Newlands, (unknown), M.H. Cullen, Stuart Kaye, Gordon Rustin, Pat Cook	89
11	Predicting etoposide toxicity: relationship to organ function and protein binding. 1996 ·Journal of Clinical Oncology ·(unknown), Ruchir Shah, Peter Clark, M L Slevin	80
12	Continuing Clozapine Despite Neutropenia 1996 ·The British Journal of Psychiatry ·(unknown), (unknown), Peter Clark	16
13	Stability of the i.v. and oral formulations of etoposide in solution 1995 ·Cancer Chemotherapy and Pharmacology ·(unknown), Peter Clark, M L Slevin	19
14	Hypersensitivity and cross-reactivity to cisplatin and analogues 1995 ·Cancer Chemotherapy and Pharmacology ·Abdul Shlebak, Peter Clark, (unknown)	47
15	Myeloma during a decade: Clinical experience in a single centre 1995 ·Annals of Oncology ·J. S. Malpas, (unknown), Peter Johnson, (unknown), (unknown), (unknown), (unknown), Peter Clark, Richard J. Osborne, M A Richards, A. Z. S. Rohatiner, M L Slevin, P. F. M. Wrigley, Tim Lister, A.H. Williams, Sharon Love, J. Amess	4
16	A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. 1994 ·Journal of Clinical Oncology ·Peter Clark, M L Slevin, (unknown), Richard J. Osborne, Denis Talbot, Peter Johnson, R H Reznek, Tahsin Masud, W. Gregory, P. F. M. Wrigley	102
17	Successful treatment of a primary endodermal sinus tumor of the liver 1992 ·Cancer ·Jeremy Whelan, (unknown), (unknown), R Y Calne, Peter Clark	13
18	A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. 1989 ·Journal of Clinical Oncology ·M L Slevin, Peter Clark, (unknown), Simran Malik, Richard J. Osborne, W. Gregory, Donna Lowe, R H Reznek, P. F. M. Wrigley	392
19	Chemotherapy for stomach cancer. 1987 ·BMJ ·Peter Clark, M L Slevin	5
20	The Clinical Pharmacology of Etoposide and Teniposide 1987 ·Clinical Pharmacokinetics ·Peter Clark, M L Slevin	209

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact